Oncology

Reportlinker: F. Hoffmann-La Roche Ltd. Company Profile Just Released: Reported Sales and...

pharmiweb.co.uk
14-Nov-2008 6 related
        

NEW YORK--(BUSINESS WIRE)--Nov 13, 2008 - Reasons to Purchase *Benchmark Roche's performance against key rivals in the prescription pharmaceutical sector *See how the Swiss company will continue to benefit from its relationship...

add comment
                   

Cancer treatment leads to bone loss

newstrackindia.com
14-Nov-2008 12 related
        

Washington, November 14 (ANI): Canadian researchers say that treatments for breast and prostate cancers may result in bone loss. Dr. Fred Saad, director of urologic oncology at the Universite de Montreal's Faculty of Medicine...

add comment
                   

HPV Vaccine Effective in Males

cancerconsultants.com
14-Nov-2008 97 related
        

Gardasil® (Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine), the vaccine approved for the prevention of cervical cancer and other HPV-related conditions in women, has now been shown to prevent...

add comment
drugpolicycentral.com: :-] Bot! - home drugpolicycentral.com

UPMC and GE Healthcare partner to develop international oncology centers

pharmaceutical-business-review.com
14-Nov-2008 20 related
        

The University of Pittsburgh Medical Center has announced collaboration with GE Healthcare, a unit of General Electric Company, to develop cancer centers internationally. This effort will provide the University of Pittsburgh...

add comment

PharmaVigilant launches electronic capture database for Phase I/II cancer study

pharmaceutical-business-review.com
14-Nov-2008
        

PharmaVigilant, a provider of clinical research solutions, has launched an electronic data capture database for a Phase I/II oncology study in four weeks for Threshold Pharmaceuticals. The clinical trial design includes three...

add comment
                   
genengnews.com: Genetic Engineering genengnews.com

INNO-406 Demonstrates Positive Clinical Responses In Phase 1 Trial In Patients With Chronic...

medicalnewstoday.com
13-Nov-2008 5 related
        

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that INNO-406, CytRx's potent, orally available, rationally designed, dual...

add comment
                   

Overall Survival in 1st-line NSCLC Reaches 15 Months With Erbitux

pharmiweb.co.uk
14-Nov-2008 5 related
        

” said Dr Ulrich Gatzemeier of the Hospital Grosshansdorf, Germany, one of the lead FLEX trial investigators. The FLEX trial was a multinational, randomized, Phase III study which involved a total of 1,125 patients with stage...

add comment
                   
genengnews.com: Genetic Engineering genengnews.com

OHSU Knight Cancer Institute researcher: study may result in more targeted drugs for GIST

brightsurf.com
13-Nov-2008 3 related
        

According to Oregon Health & Science University Knight Cancer Institute researchers, there is strong evidence that patients can have varying clinical responses to medications depending on the specific makeup of their cancer.

add comment
                   

Hana Biosciences Reports Third Quarter 2008 Results

primezone.com
13-Nov-2008 1,132 related
        

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced its financial results and...

add comment
                   
genengnews.com: Genetic Engineering genengnews.com

Research demonstrates differing genetic makeup of lung cancer in African-American patients

genengnews.com
13-Nov-2008 6 related
        

EUREKALERT Contact: Beth Bukata bethb@astro.org American Society for Therapeutic Radiology and Oncology Informs clinical development of EGFR inhibitor drugs The tumors of African-American non-small cell lung cancer patients are...

add comment